Americans Demand Transparency In Drug Pricing

The 340B drug pricing program started as a way to help patients afford life-saving medicine but today, drug companies are too often placing profits over patients. Among the largest criticisms of the program is the lack of transparency it allows for. Most states don’t mandate reports from 340B covered entities, allowing them to use savings to expand large hospital networks and line the pockets of healthcare CEOs without passing benefits onto patients. Our Health Equity advocates for large scale reforms to the 340B program that ensure patients have access to the medicine they need at a reasonable price. Read more here.